BioSpace News Archive

BD, a leading global medical technology company, announced that it will present at the following healthcare conferences.

CVS Health® announced that it has launched Cordavis, a wholly owned subsidiary that will work directly with manufacturers to commercialize and/or co-produce biosimilar products for the U.S. pharmaceutical market.

APRINOIA Therapeutics announced a mutual termination of its previously announced business combination agreement with Ross Acquisition Corp II, a special purpose acquisition company.

Samsung Biologics, a global contract development and manufacturing organization, announced the appointments of Gail Ward as Executive Vice President and Head of the Quality Center, and Sojeong Lee as Vice President and Head of Regulatory Affairs.

SK bioscience announced that the company has entered into a collaboration agreement with Vaxxas, an Australian biotechnology company developing a unique vaccine patch platform technology, to develop a second-generation typhoid conjugate vaccine with support from Wellcome.

PeptiGrowth Inc and Orizuru Therapeutics, Inc have entered into a joint development agreement to create a novel synthetic peptide that will replace a recombinant growth factor used in the manufacturing of regenerative medicine product developed by OZTx.

Abivax SA announced the appointment of Patrick Malloy as new Senior Vice President Investor Relations.

Integrated Endoscopy today announced the availability of two new versions of its flagship product, the NUVIS (pronounced “nu-vee”) Single-Use Arthroscope, making the technology accessible to surgeons using a variety of arthroscopic surgical platforms.

Qosina Corp., a global supplier of OEM single-use components to the medical and biopharmaceutical industries, is proud to be certified by Great Place To Work® for the second year in a row.

Crucial Data Solutions, Inc. (CDS), the only SaaS provider to empower customer-driven global clinical trials for web and mobile environments, is announcing an industry first milestone, surpassing 8,000 clinical trials and non-interventional studies in TrialKit, all of which have been entirely designed, deployed, and managed by CDS customers.